key: cord-0336063-c6hk5dqi
authors: Chau, Sabrina; Gao, Jie; Diao, Annette J.; Cao, Shi Bo; Azhieh, Amirahmad; Davidson, Alan R.; Meneghini, Marc D.
title: Diverse innate immune factors protect yeast from lethal viral pathogenesis
date: 2022-05-20
journal: bioRxiv
DOI: 10.1101/2022.02.14.480455
sha: 53c54ea7f99f48def93e43bf9d621b29ba56acbb
doc_id: 336063
cord_uid: c6hk5dqi

In recent years, newly characterized anti-viral systems have proven to be remarkably conserved from bacteria to mammals, demonstrating that unique insights into these systems can be gained by studying microbial organisms. Despite the enthusiasm generated by these findings, the key microbial model organism Saccharomyces cerevisiae (budding yeast) has been minimally exploited for studies of viral defense, primarily because it is not infected with exogenously transmitted viruses. However, most yeast strains are infected with an endogenous double stranded RNA (dsRNA) virus called L-A, and previous studies identified conserved antiviral systems that attenuate L-A replication. Although these systems do not completely eradicate L-A, we show here that they do prevent proteostatic stress and lethality caused by L-A over-proliferation. Exploiting this new finding, we demonstrate that the genetic screening methods available in yeast can be used to identify additional conserved antiviral systems. Using these approaches, we discovered antiviral functions for the yeast homologs of polyA-binding protein (PABPC1) and the La-domain containing protein Larp1, which are both involved in viral innate immunity in humans. We also identified new antiviral functions for the RNA exonucleases REX2 and MYG1, both of which have distinct but poorly characterized human and bacterial homologs. These findings highlight the potential of yeast as a powerful model system for the discovery and characterization of conserved antiviral systems. Significance Statement The budding yeast Saccharomyces cerevisiae has been minimally exploited for investigation of host-virus interactions despite its chronic infection with a double-stranded RNA virus called L-A. Controverting its presumed harmless nature, we show here that L-A causes pathogenesis in cells lacking parallel-acting viral attenuation pathways. Taking advantage of the genetic tools available in budding yeast, we identify several highly conserved proteins to play a role in antiviral defense. Some of these have been recently identified in humans to be involved in viral innate immunity, thus highlighting the potential of budding yeast as a model organism to identify and investigate new antiviral systems.

All laboratory strains and many environmental isolates of the budding yeast S. cerevisiae are infected with a double stranded RNA (dsRNA) virus called L-A (1, 2). L-A belongs to the broadly dispersed Totiviridae family of endogenous dsRNA viruses. Like all viruses of this family, the L-A dsRNA genome is packaged within a virion that shields it from host-mediated digestion. Holes in the virion permit the extrusion of RNA transcripts into the cytosol that encode the capsid proteins (Gag) that comprise most of the particle. The L-A transcript also encodes a Gag-pol fusion protein produced at much lower levels than the Gag protein that possesses RNA dependent RNA polymerase activity. Each virion contains a Gag-pol protein, which accounts for L-A replication and transcription within the particle. Encapsidation of the viral transcripts within nascent particles and synthesis of the negative RNA strand by Gag-pol to form the dsRNA genome completes the L-A replication cycle (2) . To produce these proteins, L-A employs features typical of RNA viruses found in humans, including a "capsnatching" mechanism that furnishes L-A transcripts with a 5'-methyl cap and a ribosomal frameshifting mechanism to produce Gag and Gag-pol fusion proteins (3, 4) .

Recent studies of bacterial antiviral systems have shown that they share remarkable evolutionary conservation with humans, revealing the potential of microbial organisms for revealing new insights into viral innate immunity (5) (6) (7) (8) (9) (10) (11) . Indeed, early studies involving L-A led to the discovery of two antiviral systems that have subsequently been shown to contribute to innate immunity against diverse RNA viruses in mammals (12) (13) (14) (15) (16) (17) . The first of these antiviral systems involves the SKI2, 3, and 8 genes, which encode subunits of a conserved ribosome-associated complex that opposes the translation of transcripts that lack poly(A) tails like those encoded by L-A (18) (19) (20) (21) (22) (23) . A separate pathway of L-A attenuation is provided by Xrn1, a 5'-3' exoribonuclease that degrades uncapped mRNAs (24) (25) (26) .

We recently found that the mitochondrial DNA/RNA endonuclease Nuc1 repressed the accumulation of L-A in sporulating cells, representing a new yeast antiviral pathway (27) . Nuc1 is a homolog of endonuclease G (EndoG) found in all eukaryotes and many prokaryotes and is most well-known for its role promoting genome fragmentation during mammalian programmed cell death, a prominent lastresort mechanism of viral defense (28, 29) . Intriguingly, programmed cell death is intrinsic to yeast sporulation, and Nuc1 fragments the DNA from dying meiotic products during this process in addition to its role in attenuating L-A viral levels that are inherited by the surviving spores (27, 30, 31) .

Despite the ubiquitous presence of the L-A virus in lab strains, no fitness consequence has been attributed to it and L-A has earned a reputation as a harmless commensal. Resultingly, although budding yeast has been a powerful system for studies of molecular and cellular biology, it is not widely known as a model for studying antiviral immunity. We show here that L-A infection is deadly for yeast and that it must be actively attenuated through viral innate immunity to preserve viability. Specifically, in strains lacking parallel acting NUC1 and SKI antiviral pathways, L-A copy number is massively increased, and this condition leads to proteostatic stress and lethality at high temperature.

Given the similarities between the L-A viral replication cycle and those of other RNA viruses, we reasoned that further characterization of L-A and the factors that maintain its replication at a low level could reveal new antiviral systems. Identification of conditions that lead to L-A pathogenesis allowed us to use bioinformatic and forward genetic screening approaches to discover new antiviral functions for the RNA exonucleases REX2 and MYG1, both of which have distinct but poorly characterized human and bacterial homologs (32) (33) (34) (35) . For MYG1, we show that its human homolog can perform antiviral activity in yeast. We also identify antiviral functions for the yeast homologs of poly(A)-binding protein (PABPC1) and the La-domain containing protein Larp1, which are both involved in viral innate immunity in humans (36, 37) . These findings provide new examples of innate immune conservation from microbes to humans and highlight the potential of yeast as a powerful model system for the discovery of new antiviral mechanisms.

Our previous studies of NUC1 were focused on meiotic cells (27) . To investigate NUC1 antiviral function in vegetatively growing yeast, we examined L-A copy number in mitotic haploid cells in the reference BY4742 strain background. We observed the levels of L-A dsRNA using ethidium bromide staining of electrophoresed RNA and found that while nuc1∆ and ski3∆ single mutants had levels similar to wild type, a nuc1∆ ski3∆ double mutant showed a large increase in L-A dsRNA (Fig. 1A) . We corroborated these findings using immunofluorescence microscopy with a dsRNA antibody widely used to detect replicating RNA viruses (38, 39) . These images showed that L-A dsRNA accumulated in foci, reminiscent of "viral factory" sites of viral replication observed in human cells ( Fig. 1B and S1 ) (40) .

Consistent with previous findings in other strain backgrounds (24, 27, 41) , western blotting showed that Gag protein levels were elevated in the nuc1∆ and ski3∆ mutants ( Fig. 2A) . Furthermore, we showed that a nuc1∆ ski3∆ double mutant accumulated a massively elevated level of Gag (Fig. 2A) . These data show that NUC1 and SKI3 participate in separate antiviral pathways and that loss of both pathways results in a greatly increased L-A viral load.

To determine if high L-A viral load affects cell fitness, we examined cellular growth using spot test growth assays. Subtle growth defects of nuc1∆ and ski3∆ single mutants were observed at 37˚ C when cells were grown with glycerol rather than glucose as the carbon source, a condition under which yeast relies on mitochondrial respiration (Fig. 2B) . Remarkably, although nuc1∆ ski3∆ double mutants grew normally at 30˚ C, they exhibited conditional lethality at 37˚ C regardless of carbon source (Fig. 2B) . As expected, viability at high temperature was restored to a nuc1∆ ski3∆ double mutant by a NUC1expressing plasmid which elicited a corresponding decrease in Gag levels ( Fig. 2A and 2B ). To confirm that the growth defect of the nuc1∆ ski3∆ double mutant was caused by L-A, we constructed an isogenic strain cured of L-A (L-A 0 ) and assayed for its growth at high temperature. We found that the growth defect was completely alleviated, implying that the conditional lethality was a result of unrestricted L-A replication (Fig. 2B) .

To further test how NUC1 interacts with known antiviral pathways, we characterized its relationship with XRN1. We found that a nuc1∆ xrn1∆ double mutant accumulated greatly elevated levels of Gag compared with either single mutant and exhibited L-A-dependent conditional lethality at high temperature ( Fig. S2A and S2B) , suggesting that NUC1 and XRN1 act in parallel pathways to attenuate L-A. Reflecting their key and non-redundant roles in bulk mRNA regulation, an xrn1∆ ski3∆ double mutant is inviable, even in strains lacking L-A (42) . To determine if XRN1 represents an antiviral system independent of both NUC1 and SKI3, we used a high-copy plasmid to overexpress XRN1 in a nuc1∆ ski3∆ double mutant. Indeed, we observed a substantial decrease in Gag levels and suppression of the nuc1∆ ski3∆ conditional lethality using plasmid driven XRN1 over-expression ( Fig. 2A and 2B) . We conclude that Nuc1, Ski3 and Xrn1 convergently oppose L-A replication and that massively increased L-A viral load in nuc1∆ ski3∆ mutants caused lethal pathogenesis at high temperature (Fig. 2C) .

The L-A-dependent conditional lethality of nuc1∆ ski3∆ double mutants opened the possibility that other antiviral factors could be identified through combinatorial mutant studies. To identify new candidate antiviral factors, we searched a curated genetic interaction database for gene deletions that caused a synthetic growth defect when combined with nuc1Δ in at least two high-throughput screening studies (43) . In addition to the expected presence of XRN1 and SKI deletions in this data set, we found sixteen additional genes. We used genetic crossing to make triple mutants combining deletions of each of these sixteen genes with nuc1∆ ski3∆ and found five that caused severe L-A dependent growth defects (Table S1 ). Here we describe two of these genes that we have confirmed as new antiviral factors.

The first new antiviral gene identified in our screen, REX2, encodes a 3'-5' RNA exonuclease conserved from bacteria to humans (33) . Both Rex2 and its human homolog REXO2 localize to the mitochondria and contain an EXOIII domain widely found in prokaryotic and eukaryotic proteins, including the interferon stimulated antiviral protein ISG20 (34, 35, (44) (45) (46) . We found that a rex2∆ nuc1∆ double mutant strain accumulated greatly increased levels of Gag and exhibited L-A-dependent lethality at high temperature ( Fig. 3A and 3B) . Remarkably, nuc1∆ ski3∆ rex2∆ and nuc1∆ xrn1∆ rex2∆ triple mutants were inviable under all growth conditions and these defects were reversed in L-A 0 strains (Fig.   S3 ). These findings demonstrate the severe pathogenic potential of the L-A virus and identify a new antiviral role for a highly conserved mitochondrially localized RNA exonuclease (Fig. 2C) .

The second gene identified in our screen was MYG1, the yeast homolog of human MelanocYte proliferation Gene 1, a 3'-5' RNA exonuclease which has homologs found in all taxa (32) . A myg1∆ nuc1∆ double mutant strain exhibited a large increase of Gag accumulation compared to the single mutants and displayed a severe L-A-dependent growth defect at high temperature (Fig. 3C, 3D , and S4A). We were able to recover nuc1∆ ski3∆ myg1∆ triple mutants, though they were extremely slow growing at 30˚ C and accumulated even higher levels of Gag ( Fig. 3C and 3D ). These growth defects were also reversed in L-A 0 strains (Fig. S4A) . MYG1 thus represents a new viral attenuation factor, acting in parallel to both NUC1 and the SKI complex (Fig. 2C) .

Mutations leading to overexpression of human MYG1 are associated with the auto-immune disorder vitiligo, suggesting that human MYG1 may play some role in normal innate immunity (47, 48) . We explored this possibility using a plasmid expressing human MYG1 under the control of a constitutive yeast promoter (32) and found that human MYG1 rescued the conditional growth defect of a nuc1∆ myg1∆ mutant (Fig. S4B) . These findings show that the antiviral function of yeast MYG1 can be accomplished by human MYG1.

Since XRN1 over-expression suppressed the growth defects of a nuc1∆ ski3∆ strain, we hypothesized that over-expression of other antiviral factors would produce a similar effect and that this phenomenon could be used as a screen to identify new antiviral systems. We employed a high-copy plasmid suppression screen to detect genes whose overexpression alleviated the conditional lethality of a nuc1Δ ski3Δ strain (see Methods). Using this screen, we identified SRO9, SLF1, and PAB1 as high-copy suppressors of nuc1∆ ski3∆, all of which encode ribosome-associated RNA binding proteins (Fig. 4A ) (49, 50) . Sro9 and Slf1 are paralogous lupus-autoantigen (La) domain containing proteins broadly found in eukaryotes. Notably, their human homolog, Larp1, was recently identified in screens for proteins bound to the SARS-Cov-2 plus strand ssRNA or nucleocapsid (36, 51) . Larp1 was a major focus in one of these studies and was shown to attenuate SARS-Cov-2 replication in human cells, though its mechanism is not known (36) . PAB1 encodes the highly conserved PolyA-Binding Protein, which is a common target of viral inhibition in humans through diverse mechanisms (37) .

We found that overexpression of PAB1 or SRO9 markedly reduced Gag levels in a nuc1∆ ski3∆ mutant, explaining their rescuing phenotypes (Fig. 4B) . Curiously, even though SLF1 overexpression rescued the nuc1∆ ski3∆ growth defect just as well as SRO9, it did not lead to any reduction in Gag levels ( Fig. 4A and 4B) . These findings suggest that PAB1 and SRO9 rescue cells by suppressing L-A replication and that SLF1 protects cells from the pathogenic consequences of elevated viral replication (Fig. 2C) .

To gain insight into the divergent mechanisms of Sro9 and Slf1 antiviral activities, we considered what the physiological consequences L-A pathogenesis could be and how SRO9/SLF1 might differentially impact them. We noted a previous study in which deletions of NUC1 or of SKI-complex genes led to weak induction of a GFP reporter gene controlled by Hsf1 (52), a conserved transcription factor that senses proteostatic stress and activates the gene expression response (53) (54) (55) . Using flow cytometry with this reporter (HSE-GFP), we confirmed these results and determined that a nuc1∆ ski3∆ double mutant caused synergistic and L-A-dependent activation of HSE-GFP (Fig. 4C and S5A) . We hypothesized that the massive accumulation of Gag observed in nuc1∆ ski3∆ mutants accounted for this proteostatic stress response. Supporting this, HSE-GFP activation of a nuc1∆ ski3∆ double mutant was reverted by PAB1 or SRO9 over-expression, mirroring these genes consequences for Gag accumulation ( Fig. 4B and 4C) . Surprisingly, over-expression of the SRO9 paralog SLF1 did not prevent HSE-GFP activation. The evolutionary divergence of SRO9 and SLF1 has thus resulted in different antiviral mechanisms, with SRO9 suppressing viral protein accumulation and associated proteostatic stress, and SLF1 possibly protecting cells from the toxic consequences of viral induced proteostatic stress (Fig.   2C ).

Proteostatic defects are often associated with the accumulation of cytotoxic protein aggregates that can be visualized using a GFP fusion of Hsp104, a protein disaggregase that localizes to sites of protein aggregation (56) . To further explore the proteostatic defects associated with L-A pathogenesis we used fluorescence microscopy to visualize Hsp104-GFP foci in a variety of strains. As expected, wild type cells grown at 30˚ C rarely accumulated observable Hsp104-GFP foci. While nuc1∆ and ski3∆ single mutants resembled wild type, strikingly, a nuc1∆ ski3∆ double mutant exhibited more than 25% of cells with 3 or more Hsp104-GFP foci (Fig. 4D) . As with all other phenotypes we have observed for nuc1∆ ski3∆, its accumulation of Hsp104-GFP foci was dependent on the presence of L-A (Fig. 4D) . These findings show that high viral load caused by deletion of NUC1 and SKI3 led to the accumulation of Hsp104-GFP foci indicative of cytotoxic protein aggregation.

The L-A dsRNA virus infects all lab strains and accompanies virtually every yeast experiment.

Despite its ubiquitous presence, L-A has been largely overlooked due to its apparent benign nature.

Here, we show that L-A has profound consequences for yeast when its replication is uncontrolled, and that diverse innate immune pathways maintain L-A replication at a tolerable level. Specifically, we show that in strains lacking the parallel-acting NUC1 and SKI3 antiviral genes, L-A replication is massively upregulated, leading to proteostatic stress and conditional lethality at high temperature. Leveraging this new discovery, we used bioinformatic and forward genetic screens to identify new yeast genes that function to restrict L-A replication or to protect cells from the pathogenic consequences of unrestrained L-A replication. As these screens were not saturating, they suggest that the yeast genome likely encodes numerous other antiviral/viral protective factors.

attenuation is puzzling. An explanation for this paradox is that L-A provides a counterbalancing benefit.

One possible benefit of L-A is that it enables some strains to maintain satellite viruses that encode secreted toxins that kill neighboring uninfected cells. However, L-A is present in many strains that lack "Killer" satellites, so this explanation is insufficient to explain the persistence of L-A infection. We thus speculate that L-A may have some additional benefit that counterbalances its deleterious potential.

Our discovery of Rex2 as a viral attenuation factor expands the arsenal of known mitochondrial antiviral factors beyond Nuc1 and suggests that mitochondria are a key antiviral hub in yeast. Indeed, mitochondria serve central roles in viral defense as a programmed cell death regulator and as a platform for antiviral signaling in humans. How do mitochondrial nucleases attenuate a virus that resides in the cytosol in yeast? One possibility is that these enzymes, while targeted to mitochondria, may nevertheless accumulate to low but sufficient levels in the cytosol to accomplish L-A attenuation directly. Consistent with this hypothesis, we showed previously that Nuc1 accumulates to low levels in the cytosol of meiotic cells, though our methods could not detect it in the cytosol of mitotic cells (27) . Another hypothesis is that some aspect of the L-A replication cycle occurs in intimate association with mitochondria. For example, L-A transcripts may associate with and possibly traverse mitochondria, thus exposing them to Nuc1 and/or Rex2. It is interesting to note that human MYG1 protein exhibits dual mitochondrial/nucleolar localization, though yeast Myg1 has only been observed in the nucleus and cytosol (32) . Our results highlight a potential general importance of mitochondria for viral innate immunity in eukaryotes and position the yeast-L-A system as a powerful model for further studies of this topic.

The antiviral SKI complex associates with translating ribosomes and our identification of Pab1, Sro9, as Slf1 as high copy suppressors of L-A pathogenesis further reveal the translating ribosome as a key hub of yeast antiviral activity. The finding that PAB1 (polyA binding protein) repressed L-A is surprising given the absence of polyA tails in L-A transcripts, suggesting that Pab1 does not act on L-A directly. Previous findings showed that L-A transcripts compete with polyA+ yeast mRNAs for capture of 60S ribosomal subunits to form translating 80S complexes (57) . One model explaining these findings is that Pab1 enhances the translation of polyA tail containing mRNAs, which then deplete the availability of 60S subunits for L-A transcripts for translation. The roles of Sro9 and Slf1 in translation n are less well understood, but their functions may similarly relate to competition of L-A transcripts for 60S subunits. Importantly, the homologs of Pab1 and Sro9/Slf1 are involved in human viral defense and further studies of these genes in yeast will shed light on antiviral mechanisms conserved from yeast to human.

Standard S. cerevisiae genetic and strain manipulation techniques were used for strain construction.

Strains were grown at 30°C in either YPAD or synthetic complete media with appropriate amino acid drop out for plasmid maintenance unless otherwise specified. Refer to Table S2 for strains and plasmids used in this paper. The yOB255 URA3::HSE-EmGFP strain was obtained from Onn Brandman (58) . The

LEU2, p5476 SLF1 2μ LEU2 MOBY plasmids were obtained from Brenda Andrews (59) . The pVB3011 L-BC GAG (PGAL1) plasmid was obtained from Suzanne Sandmeyer (60) . The RLY8470 trp::mCherry-FIS1TM-KanMX; HSP104-GFP-HIS3 strain was obtained from Rong Li (61) .

Yeast strains were grown overnight at 30°C to saturation. Each strain was diluted to an OD600 = 0.4, serial diluted four times by 10-fold, and spotted onto agar plates containing synthetic complete media or drop out media supplemented with the indicated carbon source (2% glucose or 3% glycerol). 

L-A 0 strains were generated similar to as we described previously (27) . Briefly, a progenitor L-A 0 strain was isolated following treatment with 32 mM Anisomycin (BioShip ANS245) for 4 days in YPD media and plating for single colonies. Isolates were tested for the presence of the L-A genome by RT-PCR.

This L-A 0 strain was then used for subsequent backcrossing with mak3Δ to generate other L-A 0 strains.

To evict L-BC, cells were transformed with the L-BC GAG (PGAL1) plasmid and grown overnight in -URA drop out media supplemented with 2% raffinose. The saturated culture was diluted and grown in raffinose to log phase before treated with 2% galactose for 24 hours. The resulting culture was plated for single colonies on an agar plate containing synthetic complete media supplemented with 5-FOA. Isolates were tested for the presence of the L-BC genome by RT-PCR.

10 OD of log phase cells was harvested and resuspended in phenol solution (P4682; Sigma-Aldrich), SDS, and buffer AE (10 mM Tris·Cl and 0.5 mM EDTA, pH 9.0). Samples were incubated at 65°C for 30 minutes, and the phase-separated supernatant was washed with chloroform and precipitated in isopropanol overnight. The precipitate was washed with 70% ethanol and dissolved in water. RNA samples were then purified with the RNeasy Mini Kit (Qiagen). Four micrograms of RNA were reversetranscribed using random nonamers and Maxima H Minus Reverse Transcriptase (Thermo Fisher). The cDNA product was isolated by alkaline hydrolysis and treated with RNase A.

Log phase cells were fixed with 4% formaldehyde and washed 2 times with 1x phosphate-buffered saline (PBS). Cells were resuspended in sorbitol buffer (1.2 M sorbitol and 20 mM potassium phosphate buffer, pH 7.2) and spheroplated with β-mercaptoethanol (M7522; Sigma-Aldrich) and zymolase at 30°C. Spheroplasted cells were added onto polylysine coated slides and incubated with primary antibody 1:1000 J2 anti-dsRNA (SCICONS) overnight. The cells were detected with 1:1000 cyanine3 conjugated goat anti-mouse (Jackson ImmunoResearch Laboratories) and stained with DAPI. The images were acquired on the Zeiss Axio Imager Z1 with Volocity and processed with ImageJ.

Log phase cells were stained with propidium iodide, fixed with 4% formaldehyde, and washed 3 times with 1x PBS. Fluorescence intensity was measured with Becton Dickinson LSR II flow cytometer and analyzed with Flowing Software. The median GFP intensities of three biological replicates were plotted using R studio ggplot2.

Log phase cells were fixed with 4% formaldehyde and washed 3 times with 1x PBS. Fixed cells were mounted onto microscopy slide and stained with DAPI. Images were acquired with Leica Sp8 confocal LSM and processed with Leica Application Suite (LAS X). The deconvolution program Lightning was applied to all images.

A plasmid library of random genomic inserts in the YEP24 plasmid backbone was transformed into a nuc1Δ ski3Δ strain and grown on -URA agar plates at high density (63) . Lawns of transformants grown at 30˚ C were replica plated to 37˚ C and potential suppressors were obtained from the colonies that grew at this temperature. To confirm that the suppression was plasmid dependent, the potential suppressors were first grown on agar plate containing 0.1% 5-fluoroorotic acid (5-FOA) for counterselection and then transferred to a fresh agar plate at 37°C supplemented with glycerol. The plasmids of the candidates were isolated and sequenced to identify potential genes responsible for the suppression of L-A pathogenesis when over-expressed. The candidate genes were confirmed by spot analysis using p5476 MOBY plasmids.

Data was tested for statistical significance using Excel and plotted with R studio ggplot2. The details of the statistical tests are described in the figure legends. WT nuc1 ski3 L-A + L-A 0 nuc1 ski3 Figure S5 . L-A pathogenesis correlates with proteostatic stress. Flow cytometry was used to measure HSE-GFP expression in the indicated strains. Median GFP intensity is shown. n = 3. * p < 0.05, ** p < 0.01. The p value was calculated using unpaired student's t-test. none none none n/a n/a far3 none none none n/a n/a fks1 none none none n/a n/a gcr2 none none none n/a n/a ntg2 none none none n/a n/a pbs2 none none none n/a n/a sur1 none none none n/a n/a sut2 none none none n/a n/a Table S2 . Sixteen new candidate antiviral factors were identified using a bioinformatic approach. Deletion mutants for each of these candidates were crossed to a nuc1∆ ski3∆ mutant and dissected. Phenotypes were scored as indicated and "conditional" indicates synthetic growth defects at temperatures at 37˚ C and/or under glycerol conditions at 30˚ C and 37˚ C. n.d. = not determined. *Mutants combined with nuc1∆ ski3∆ exhibit enhanced conditional growth phenotypes at 35˚ C compared with nuc1∆ ski3∆.

Viruses and prions of Saccharomyces cerevisiae

Cap-snatching mechanism in yeast L-A double-stranded RNA virus

A -1 ribosomal frameshift in a double-stranded RNA virus of yeast forms a gag-pol fusion protein

Prokaryotic viperins produce diverse antiviral molecules

The pan-immune system of bacteria: antiviral defence as a community resource

Bacterial gasdermins reveal an ancient mechanism of cell death

STING cyclic dinucleotide sensing originated in bacteria

Antiviral activity of bacterial TIR domains via immune signalling molecules

cGAS-like receptors sense RNA and control 3'2'-cGAMP signalling in Drosophila

Bacterial cGAS-like enzymes synthesize diverse nucleotide signals

Cellular 5'-3' mRNA exonuclease Xrn1 controls double-stranded RNA accumulation and anti-viral responses

The SKIV2L RNA exosome limits activation of the RIG-I-like receptors

DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling

Spatio-temporal characterization of the antiviral activity of the XRN1-DCP1/2 aggregation against cytoplasmic RNA viruses to prevent cell death

RNA degradation in antiviral immunity and autoimmunity

IL-1beta/ATF3-mediated induction of Ski2 expression enhances hepatitis B virus x mRNA degradation

The yeast antiviral proteins Ski2p, Ski3p, and Ski8p exist as a complex in vivo

Decoying the cap-mRNA degradation system by a double-stranded RNA virus and poly(A)-mRNA surveillance by a yeast antiviral system

The cryo-EM structure of a ribosome-Ski2-Ski3-Ski8 helicase complex

3' poly(A) is dispensable for translation

Chromosomal superkiller mutants of Saccharomyces cerevisiae

Extraction of mRNA from Stalled Ribosomes by the Ski Complex

Genetic Control of L-a and L-(Bc) Dsrna Copy Number in Killer Systems of SACCHAROMYCES CEREVISIAE

20S RNA narnavirus defies the antiviral activity of SKI1/XRN1 in Saccharomyces cerevisiae

XRN1 Is a Species-Specific Virus Restriction Factor in Yeasts

Meiotic viral attenuation through an ancestral apoptotic pathway

Endonuclease G is an apoptotic DNase when released from mitochondria

Viruses and apoptosis

Developmentally programmed nuclear destruction during yeast gametogenesis

Developmental Coordination of Gamete Differentiation with Programmed Cell Death in Sporulating Yeast

Myg1 exonuclease couples the nuclear and mitochondrial translational programs through RNA processing

A conserved ancient domain joins the growing superfamily of 3'-5' exonucleases

Human REXO2 controls short mitochondrial RNAs generated by mtRNA processing and decay machinery to prevent accumulation of double-stranded RNA

Exoribonuclease superfamilies: structural analysis and phylogenetic distribution

The SARS-CoV-2 RNA-protein interactome in infected human cells

Poly(A)-binding protein (PABP): a common viral target

Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses

Composition and three-dimensional architecture of the dengue virus replication and assembly sites

Virus assembly factories in a lipid world

Overproduction of yeast viruslike particles by strains deficient in a mitochondrial nuclease

Synthetic lethality of sep1 (xrn1) ski2 and sep1 (xrn1) ski3 mutants of Saccharomyces cerevisiae is independent of killer virus and suggests a general role for these genes in translation control

BioGRID: a general repository for interaction datasets

ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses

YNT20, a bypass suppressor of yme1 yme2, encodes a putative 3'-5' exonuclease localized in mitochondria of Saccharomyces cerevisiae

Three conserved members of the RNase D family have unique and overlapping functions in the processing of 5S, 5.8S, U4, U5, RNase MRP and RNase P RNAs in yeast

Correlation of increased MYG1 expression and its promoter polymorphism with disease progression and higher susceptibility in vitiligo patients

MYG1, novel melanocyte related gene, has elevated expression in vitiligo

Two yeast La motif-containing proteins are RNA-binding proteins that associate with polyribosomes

Ribosomal association of poly(A)-binding protein in poly(A)-deficient Saccharomyces cerevisiae

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

A ribosome-bound quality control complex triggers degradation of nascent peptides and signals translation stress

Regulation of HSF1 function in the heat stress response: implications in aging and disease

Rethinking HSF1 in Stress, Development, and Organismal Health

Purification and characterization of a heat-shock element binding protein from yeast

Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins

Yeast virus propagation depends critically on free 60S ribosomal subunit concentration

Aggregation of CAT tails blocks their degradation and causes proteotoxicity in S. cerevisiae

Dosage suppression genetic interaction networks enhance functional wiring diagrams of the cell

Ty3 Retrotransposon Hijacks Mating Yeast RNA Processing Bodies to Infect New Genomes

Cytosolic proteostasis through importing of misfolded proteins into mitochondria

Porin Associates with Tom22 to Regulate the Mitochondrial Protein Gate Assembly

Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization

We are grateful Dr. Charlie Boone and Dr. Brenda Andrews for generous sharing of strains and plasmid 

We declare no competing financial interests.

All data is available in the main text or supplementary materials.